Online PSA without Knochenmarktoxizit t Significantly. Endothelin antagonists of endothelin pathway in the F Promotion Osteoblastenaktivit t, Brought a property of bone metastases in prostate cancer. Two selective endothelin antagonists were evaluated in this population and zibotentan atrasentan. Data from a study of 809 patients Ridaforolimus AP23573 showed that atrasentan CRPC, although a significant decrease in molecular markers of disease progression was observed. The same result for the TTP was observed with zibotentan, despite the improvement in overall survival in a phase II clinical trial. This vorl Ufigen results underscore the need for further evaluation in this group of patients.
There is no consensus calcitriol oncologists clinical benefit of calcitriol in the treatment of CRPC although pr Clinical data have shown that it has a potent Antitumoraktivit t Antiangiogenic with antiproliferative effects induction, and apoptosis. Calcitriol also seems to act synergistically with dexamethasone. In 2010, Chadha et al. ver the results of a Phase II clinical study with intravenous ffentlichte these calcitriol and dexamethasone in patients with CRPC. The results of this study indicate that this compound produced no clinical response or PSA. Recently, a phase III study, evaluated the efficacy of docetaxel plus high-dose calcitriol plus docetaxel compared with prednisone in 953 patients with CRPC, they reported a Erh Increase in the number of Todesf Lle, shorter overall survival and shorter treatment time in the arm contr with respect to the ASCENT l arm.
These findings led to the end of the study was the clinical development and the formulation of calcitriol was used in this study is interrupted. CONCLUSION The introduction of docetaxel in 2004 began a new Era in the treatment of CRPC. In recent years, further progress in the development of new agents with activity has t Against refractory Ren disease Verl Ufen with docetaxel and the potential that docetaxel-based first-line therapy in the near future increased Made hen. Cabazitaxel is currently the only means that can be embroidered with a chemotherapy in a Phase III clinical trial in patients with CRPC and docetaxelrefractory Sipuleucel T in some L Change in asymptomatic patients was compared. Abiraterone appears to be a new treatment option for docetaxel-refractory Another patient CPRC.
In coming years, the results of studies on these and other new drugs are likely to be increased armor for CRPC treatment Hen. Conflicts of interest: We de Ren financial support from Sanofi-aventis and reveal our EOI. Fernando C. Maluf is a consultant for Janssen Cilag and Sanofi-aventis. Daniel Herchen Horn is a researcher in the TROPIC trial. O ? s Smaletz has again Re U fees as a speaker and consultant for sanofi-aventis Oit Forschungsf promotion from Janssen Cilag. All authors are members of the advisory board of Sanofi Aventis. This work represents the views of the respective authors. Prostate cancer is the zweith Most common diagnosed cancer among Canadian M men’s. It is expected that by 2010, were diagnosed more than 24,000 Canadians with the disease and more than 4,000 Todesf Lle due to advanced